Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma

Haematologica

Volumn 86, Issue 4, 2001, Pages 399-403

  Palumbo, A ^a   Giaccone, L ^a   Bertola, A ^a   Pregno, P ^a   Bringhen, S ^a   Rus, C ^a   Triolo, S ^a   Gallo, E ^a   Pileri, A ^a   Boccadoro, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Dexamethasone; Myeloma; Salvage therapy; Thalidomide

Indexed keywords

DEXAMETHASONE; IMMUNOMODULATING AGENT; PARAPROTEIN; THALIDOMIDE;

ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; ERYSIPELAS; FOLLOW UP; HUMAN; HYPOTHYROIDISM; MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; SEDATION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0035018156     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
2. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
3. Thalidomide is an inhibitor of angiogenesis
4. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
5. Global gene expression analysis shows loss of c-myc and IL-6 receptor gene mRNA after exposure of myeloma to thalidomide and IMID
6. Treatment of multiple myeloma
7. The treatment of multiple myeloma
8. Multiple myeloma
9. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
10. Total therapy with tandem transplants for newly diagnosed multiple myeloma
11. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities
12. Antitumor activity of thalidomide in refractory multiple myeloma
13. High-dose glucocorticoid treatment of resistant myeloma
14. Prednisone pulse therapy for refractory myeloma
15. Primary dexamethasone treatment of multiple myeloma
16. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
17. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
18. Multiple myeloma, macroglobulinemia and monoclonal gammopathies
19. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients
20. Nonparametric estimation from incomplete observations
21. Therapy with thalidomide in refractory multiple myeloma patients: The revival of an old drug
22. Management of refractory myeloma: A review
23. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
24. Thalidomide in patients with advanced multiple myeloma
25. Low-dose of thalidomide in the treatment of refractory myeloma
26. Is thalidomide 50 mg/d as a minimal first dose effective in advanced myeloma?
27. Dose intensity analysis of melphalan and prednisone in multiple myeloma